Coherus BioSciences
Update in progressCHRS (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Coherus Oncology, Inc. is a Redwood City biopharmaceutical company that discovers, develops, and commercializes cancer therapies in the United States. It markets UDENYCA, a Neulasta biosimilar; LOQTORZI, a next‑gen PD‑1 inhibitor; and Casdozokitug, an investigational anti-IL‑27 IgG1 antibody. It also pursues CHS‑114 for head and neck cancer. The company collaborates with Junshi, Surface, Adimab, Bioeq, Genentech, Vaccinex, and others, with various out‑licensing deals, and was renamed in May 2025.
Company score
- Sentiment
- 0.07
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.07
- Governance
- 0.01
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.03
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMr. Dennis M. Lanfear
- Founded2010
- Employees144
- Websitewww.coherus.com
Identifiers
- ISINUS19249H1032
- FIGIBBG0063N8V69
- LEI5493007IL8W5MV932D26
- CUSIP19249H103
- CIK0001512762